

COPD in Primary Care:

Managing Expectations and Optimizing Outcomes



References and Reading

Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. *J Glob Health*. 2015;5:02415.

Anthonisen NR, Connet JE, Murray RP; for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. *Am J Respir Crit Care Med*. 2002;166:675-679.

Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J*. 2009;33:1165-1185.

Bastin AJ, Starling L, Ahmed R, Dinham A, Hill N. High prevalence of undiagnosed and severe chronic obstructive pulmonary disease at first hospital admission with acute exacerbation. *Chron Resp Dis*. 2010;7:91-97.

Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. *Resp Res*. 2013;14:109.

Calverley PMA, Walker P. Chronic obstructive pulmonary disease. *Lancet*. 2003;362:1053-1061.

Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults—United States, 2011. *MMWR Morb Mortal Wkly Rep*. 2012;61(46):938-943.

Chapman KR, Tashkin DP, Pye D. Gender bias in the diagnosis of COPD. *Chest*. 2001;119:1691-1695.

Coultas D, McKinley J. Update on pulmonary rehabilitation for COPD. *Clin Pulm Med*. 2009;16:183-188.

Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*. 2015;147(4):894-942.

Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. *Int J Chron Obstruct Pulmon Dis*. 2009;4:337-349.

Fishman AP, Martinez FJ, Naunheim KS, et al; for the National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med*. 2003;348:2059-2073.

Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance—United States, 1999-2011. *Chest*. 2013;44:284-305.

Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. *Intern J Gen Med*. 2011;4:729-739.

George J, Kong DCM, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. *Chest*. 2005;128:3198-3204.

Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. *Lancet Respir Med*. 2016;4:473-526.

Hansel NN, McCormack MC, Kim V. The effects of air pollution and temperature on COPD. *COPD*. 2016;13:372-379.

Hurst JR, Vestbo J, Anzueto A, et al; for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010;363:1128-1138.

Kochanek D, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. *Natl Vital Stat Rep*. 2016; 5(4):1-122.

Laforest L, Denis F, Van Ganse E, et al. Correlates of adherence to respiratory drugs in COPD patients. *Prim Care Resp J*. 2010;19:148-154.

Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*. 2014;371:1285-1294.

Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). *COPD*. 2008;5:85-95.

Nardini S, Camiciottoli G, Locicero S, et al. COPD: maximization of bronchodilation. *Multidisc Resp Med*. 2014;9:50.

Newman SP. Inhaler treatment options in COPD. *Eur Respir Rev*. 2005;14:102-108.

Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med*. 2011;155:179-191.

Restrepo RD, Alvarez MT, Wittnebel L, et al. Medication adherence issues in patients treated for COPD. *Int J COPD*. 2008;3:371-384.

Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. *Arch Bronconeumol*. 2012;48:331-337.

Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. *Lancet*. 2007;370:786-796.

Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. *N Engl J Med*. 2016;374:2222-2234.

Wise RA, Tashkin DP. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? *Am J Med*. 2007;120(8 Suppl 1):S14-S22.

